Azithromycin may increase hematologic relapse rates in matched unrelated donor hematopoietic cell transplant recipients who receive anti-thymocyte globulin, but not in most other recipients

Ítems similars

• Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation
  per: Mehta, Rohtesh S., et al.
  Publicat: (2016)
• Feasibility and Reliability of Home-based Spirometry Telemonitoring in Allogeneic Hematopoietic Cell Transplant Recipients
  per: Sheshadri, Ajay, et al.
  Publicat: (2020)
• The Impact of Pre-Stem Cell Transplant Ferritin Level on Late Transplant Complications: An Analysis to Determine the Potential Role of Iron Overload on Late Transplant Outcomes
  per: Efebera, Yvonne A, et al.
  Publicat: (2009)
• Anti-thymocyte globulin for conditioning in matched unrelated donor hematopoietic cell transplantation provides comparable outcomes to matched related donor recipients
  per: Portier, DA, et al.
  Publicat: (2012)
• Pilot Study Using Post-transplant Cyclophosphamide (PTCy), Tacrolimus and Mycophenolate GVHD Prophylaxis for Older Patients Receiving 10/10 HLA-Matched Unrelated Donor Hematopoietic Stem Cell Transplantation
  per: Shah, Mithun Vinod, et al.
  Publicat: (2018)